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Summary Six patients with status epilepticus (SE) of various etiologies refractory to
at least two antiepileptic drugs (AEDs) had complete cessation of their seizures
following administration of oral levetiracetam (LEV). Seizure types included con-
vulsive, focal, and nonconvulsive status epilepticus. Effective doses of levetiracetam
ranged from 500 to 3000 mg/day, achieving seizure control within 12—96 h. No
significant adverse events were noted. Adjunctive levetiracetam should be consid-
ered for patients with status epilepticus unresponsive to initial therapy.
# 2005 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Despite significant advances in the treatment of
epilepsy, status epilepticus (SE) continues to be a
medical emergency affecting more than 100,000
individuals each year with a mortality >20%.1 Sev-* Corresponding author. Tel. +1 573 882 5779;
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doi:10.1016/j.seizure.2005.12.003eral protocols for the treatment of status epilepti-
cus are in general use.2 Refractory status
epilepticus, defined as seizures lasting longer than
60 min despite treatment with a benzodiazepine
and adequate loading dose of an intravenous anti-
epileptic drug (AED)3 affects 6000—20,000 people
per year in the US and portends a mortality ranging
from 32 to 77%.4 Refractory status epilepticus is
associated with more frequent medical complica-
tions, longer hospitalizations and duration of inten-
sive care, and increased functional disability
compared to patients who responded to the first
AED after an initial benzodiazepine.3 Risk factors for. Published by Elsevier Ltd. All rights reserved.
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Table 1 Status epilepticus case summaries












1. 57 F Convulsive, focal PHT, LZP, VPA,
CBZ, PB
24 Days Left insular
vascular lesion
3000 4 Days
2. 91 M Right focal PHT, VPA 9 Days Left MCA infarct 3000 2 Days




4. 16 F Convulsive and
nonconvulsive
LZP, PB, TPM 2 Days Static
encephalopathy
500 1 Day









6. 25 F Convulsive and
nonconvulsive
LZP, MDZ, VPA, CBZ 9 Days Noncompliance 1000 36 h
CBZ, carbamazepine; GBP, gabapentin; ICH, intracerebral hemorrhage; LEV, levetiracetam; LTG, lamotrigine; LZP, lorazepam; MDZ,
midazolam; PB, phenobarbital; PHT, phenytoin; SE, status epilepticus; TPM, topiramate; VPA, valproic acid.refractory status epilepticus include nonconvulsive
status epilepticus, and focal motor seizures.3 Out-
come is closely linked to the etiology of status
epilepticus.5
Current recommendations for the treatment of
refractory status epilepticus include midazolam
(MDZ), pentobarbital, and propofol.1 Respiratory
depression and/or hypotension may result from
treatment,1 which may necessitate endotracheal
intubation and/or vasosuppressor support.6
Although individual preferences regarding thera-
peutic protocols vary, neurologists agree that treat-
ment should be started early to prevent brain injury
secondary to sustained status epilepticus.6 Visible
evidence of such injury has recently been documen-
ted on MRI.7 Despite weeks or months of high dose
suppressive therapy in an effort to control refrac-
tory status epilepticus, outcomes may not prove
satisfactory.5 Randomized controlled trials compar-
ing treatments of refractory status epilepticus have
not yet been performed.3
We present six cases of patients with status
epilepticus that persisted despite initial AED ther-
apy, but ultimately responded to treatment with
levetiracetam (LEV), a new AED. In 1999, LEV
received FDA approval as adjunctive therapy for
the treatment of partial onset seizures in adults
with epilepsy.8 Preliminary observations suggest
that LEV may be effective in generalized seizures
as well.9 LEV has a unique pharmacologic profile; it
is not metabolized by the liver, has no known drug—
drug interactions, has low protein binding (<10%), is
renally excreted, the extent of absorption is not
affected by food, and has a half life of 6—8 h inadults.10 At the time these patients were treated,
only oral tablets (250, 500, 750 mg doses) were
available. However, an oral solution (100 mg/ml)
received FDA approval in July, 2003. An intravenous
formulation is under development (personal com-
munication).
Four of these six patients fit the strict definition
of refractory status epilepticus stated above. The
other two (Cases #2 and #3) do not, because they did
not receive an initial benzodiazepine. However,
these two cases are included because they were
‘refractory’ in a clinical if not technical sense, as
they each failed both phenytoin (PHT) and valproate
therapy.
Case historiesCase 1. A 57-year-old woman with a 30-year history
of epilepsy had right-sided focal seizures with sec-
ondary generalization at home. Her phenytoin level
was ‘therapeutic’ at 16.5 mg/ml upon arrival to the
emergency room. After treatment with intravenous
lorazepam (LZP) and valproic acid (VPA), the clinical
seizures stopped, focal seizures occurred intermit-
tently. The patient did not wake up. EEG demon-
strated left temporal PLEDS. MRI revealed a left
insular lesion of uncertain age, thought to be vas-
cular. Valproic acid level increased from 57 to
79 mg/ml over the next 24 h. Phenytoin remained
at 15 mg/ml. Carbamazepine (CBZ) was begun at
200 mg Q 8 h. Right-sided focal seizures continued
and the patient became less responsive. Ammonia
was 113 mg/dl. By hospital day 18, the patient
remained unresponsive; phenytoin level was
The use of levetiracetam in refractory status epilepticus 13914 mg/ml, valproic acid 91 mg/ml, and carbamaze-
pine 5 mg/ml. Ammonia had increased to 270 mg/dl.
Phenobarbital (PB) had been added and the level
was 20 mg/ml. On hospital day 19, LEV 1000 mg
tablets were crushed and administered via NG tube
Q 8 h. Valproic acid and phenytoin were discontin-
ued. On hospital day 22, ammonia had decreased to
37 mg/dl. The patient was receiving phenobarbital
120 mg/day and her level was 35 mg/ml. LEV dose
was still 3000 mg/day. Seizures stopped on hospital
day 24, 4 days after adding LEV. By hospital day 27,
the patient was alert and oriented. She was dis-
charged on phenobarbital and LEV. Later the phe-
nobarbital was discontinued, and she remains well
controlled on LEV 2500 mg/day.
Case 2. A 91-year-old man with a history of atrial
fibrillation, hypertension, and TIAs presented with
garbled speech and right-sided facial twitching. He
had been prescribed phenytoin for questionable
seizures in the past, but had not taken it for several
years. CATscan revealed a left MCA infarct. Because
of episodes of altered consciousness thought to be
seizures, he was started on phenytoin. Despite a
therapeutic phenytoin level, the patient had right-
sided focal motor seizures and was loaded with
intravenous valproic acid, achieving a level of
95 mg/ml within 24 h. The patient became unre-
sponsive with shallow, irregular breathing and inter-
mittent right-sided seizures. EEG revealed left-
sided PLEDS. On hospital day 7, the patient contin-
ued to have seizures despite valproic acid levels of
113 mg/ml and phenytoin of 13.6 mg/ml. Conse-
quently, crushed LEV tablets were added via NG
tube at 1000 mg TID. Two days later, the patient’s
EEG was improved and it appeared that his seizures
were controlled. His phenytoin was discontinued.
On hospital day 11, his valproic acid was also dis-
continued. The patient’s level of consciousness gra-
dually improved, and his EEG suggested a postictal
state. On hospital day 12, the patient was on LEV
monotherapy 3000 mg/day. By the next day, he was
awake, alert, and had only some mild expressive
language problems. The patient was discharged to
the rehabilitation unit and within a month was
discharged home on LEV 2500 mg/day. He had no
residual right-sided weakness, and only minimal
dysphasia. Two months later he had an intracranial
hemorrhage into the region of his infarct while on
coumadin and expired.
Case 3. A 63-year-old woman was admitted with
right-sided seizures, altered mental status and
slurred speech. CAT scan showed a left frontal
lesion, possibly a hemorrhagic infarct. She was
loaded with fosphenytoin and given additional dosesof phenytoin, but continued to have seizures after
24 h despite phenytoin levels of 15—20 mg/ml.
Intravenous valproic acid was added, followed by
maintenance valproic acid therapy. On hospital day
2, her phenytoin level was 10 mg/ml and her val-
proic acid level was 84 mg/ml. She continued with
focal seizures and fluctuating levels of conscious-
ness. EEG revealed left frontal PLEDS. On hospital
day 5, she continued to have intermittent right focal
seizures and was only intermittently arousable.
Phenytoin level was 14 mg/ml and valproic acid level
was 94 mg/ml. LEV was added (500 mg BID) via NG
tube and increased to 500 mg QID over the next 24—
48 h. Two days later, on hospital day 7, she was able
to look around the room and had no more seizures.
EEG showed resolution of her seizure focus. Pheny-
toin level was 15 mg/ml, valproic acid level 61 mg/
ml, and she continued LEVat 500 mg BID. By hospital
day 10, she was fully alert. Phenytoin was discon-
tinued. Valproic acid was continued at 500 mg BID.
LEV was decreased to 1500 mg/day. After further
consultation and an MRI, the discharge diagnosis was
lupus cerebritis with CNS vasculitis and coagulopa-
thy. The patient was discharged to the rehabilitation
institute on valproic acid, LEV, and coumadin.
Case 4. A 16-year-old girl with seizures since age 6
years, static encephalopathy, Dandy—Walker syn-
drome and shunted hydrocephalus had failed treat-
ment with carbamazepine, clonazepam, phenytoin,
and valproic acid and was maintained on phenobar-
bital and topiramate (TPM). Elective spinal fusion
surgery was followed by 3—4 partial complex sei-
zures with secondary generalization. After treat-
ment with intravenous lorazepam and additional
phenobarbital (level increased from 25.6 to
33.9 mg/ml), the patient’s seizures appeared to
be controlled. However, the next day she was unar-
ousable. EEG revealed brief runs of generalized
spikes and waves every 30—40 s consistent with
nonconvulsive status epilepticus. Because the
patient had not tolerated phenytoin or valproate
in the past and was allergic to carbamazepine, she
was given 500 mg of LEV (28 mg/kg), crushed and
dissolved in water and administered via NG tube.
The following day, the patient woke up and the EEG
did not reveal any seizure activity. The patient
continued on 250 mg BID of oral LEV in addition to
phenobarbital 60 mg BID and topiramate 50 mg BID.
Case 5. A 34-year-old man with a history of post-
traumatic epilepsy was admitted with simple partial
seizures of the right arm and leg with and without
secondary generalization after noncompliance with
phenobarbital 100 mg/day (admission level 0) and
alcohol abuse. On initial examination, the patient
140 N.C. Patel et al.was confused but able to follow simple commands.
He had mild (4/5) left arm and leg weakness and a
left-sided Babinski sign. Seizures did not respond to
lorazepam or loading doses of phenobarbital or
valproic acid (Depacon 3 g), and patient was intu-
bated. (The patient did not receive phenytoin due
to a phenytoin allergy.) Chest X-ray revealed aspira-
tion pneumonia with a large pleural effusion that
required thoracentesis. Head CTrevealed bifrontal
encephalomalacia and evidence of previous cra-
niotomy and facial bone repair. Initial EEG demon-
strated bifrontal polyspike wave discharges at 3—
4 Hz lasting approximately 15 s and recurrent spikes
in the left frontal head region. EEG on day 2
revealed electrographic seizures with onset in
the left frontal region extending into the right
frontal region lasting 30—50 s. Patient received a
phenobarbital infusion of 15 mg/h and additional
valproic acid (Depacon 1 g Q 4 h). On day 3, lamo-
trigine (LTG) was begun at 100 mg Q 8 h, together
with LEV 1 g Q 8 h administered as crushed tablets
via NG tube. The patient also received intravenous
rocephin and multivitamins. The next day, after
approximately 12 h of receiving lamotrigine and
LEV, the patient had no more clinical seizures.
The EEG still had some residual spikes, but the
electrographic seizures had resolved. By the next
day, the EEG revealed only diffuse slowing. The
patient remained in hospital for 27 days. At the
time of discharge, he had mild right-sided weak-
ness. He was discharged home on lamotrigine
100 mg BID, divalproex sodium 1 g every 8 h, and
LEV 1 g BID.
Case 6. A 25-year-old woman with mild mental
retardation and seizures since the age of 5 years
had a left temporal lobectomy at age 12 years.
Between the age 12 and 25 years she continued to
have infrequent seizures despite multiple AED
adjustments. While taking carbamazepine and
valproate, the patient was admitted with convulsive
status epilepticus, likely related to medication non-
compliance (carbamazepine level 3.2 mg/ml, dival-
proex sodium 21 mg/ml). She was treated with
intravenous lorazepam, midazolam, and valproate
sodium, which stopped the convulsions after
approximately 8 h. For the following 3 days, she
remained poorly responsive with a waxing and wan-
ing mental status, originally attributed to the ben-
zodiazepine treatment. However, after cessation of
the benzodiazepines, there was no improvement in
mental status and the patient was admitted to the
epilepsy monitoring unit. Over the next 24 h, 30—40
electrographic seizures were noted and the patient
was diagnosed with nonconvulsive status epilepti-
cus. Some of the seizures were associated withminimal right facial twitching. At this time, her
carbamazepine and divalproex sodium levels were
8.2 and 94 mg/ml, respectively. LEV tablets were
added at 500 mg BID and the nonconvulsive status
epilepticus resolved 36 h later. Within the next few
days the patient returned to close to her pre-admis-
sion baseline. She was discharged on carbamazepine
600 mg BID, divalproex sodium 750 mg TID, loraze-
pam 0.5 mg BID, and LEV 500 mg BID. A few days
later the LEV was increased to 1000 mg BID and over
the following weeks to 2500 mg BID.Discussion
In these six patients, LEV proved effective in several
types of status epilepticus, including generalized,
focal, and nonconvulsive status epilepticus. Etiolo-
gies included ischemic and hemorrhagic infarcts,
static encephalopathy, CNS vasculitis, posttrau-
matic epilepsy, and noncompliance. All of these
patients had been treated with at least two and
as many as five AEDs prior to the addition of LEV. In
all six cases, seizures terminated within 12—96 h of
the first dose of LEV. No side effects attributable to
LEV were observed. Expected side effects such as
somnolence may not have been discernible due to
the clinical setting that included multiple medica-
tions and postictal state (Table 1).
Another new AED, topiramate, has recently been
reported to be effective in refractory status epilep-
ticus.11 Topiramate has multiple mechanisms of
action including voltage-sensitive, use-dependent
sodium channel blockade, similar to phenytoin.11
The mechanism by which LEVexerts its antiepileptic
effect is not known, but is likely different from
topiramate. Recent investigations of LEV have
demonstrated effects on N-type calcium channels12
and reduction of potassium currents in hippocampal
CA1 neurons.13 How topiramate and LEV succeed in
terminating status epilepticus remain under inves-
tigation.
Treatment of refractory status epilepticus typi-
cally requires intravenous pentobarbital, propofol,
or midazolam, which may necessitate intubation
and require vasopressor support. Oral AEDs such
as topiramate or LEV have much to offer if they
can pre-empt these more aggressive treatments.
The lack of drug—drug interactions associated with
LEV enhances its value in the setting of critically ill
patients with status epilepticus. The new availabil-
ity of a liquid LEV preparation and the development
of an intravenous form will also facilitate treatment
of this patient population.
Conclusions regarding LEV’s effectiveness in con-
trolling status epilepticus must be tempered by the
The use of levetiracetam in refractory status epilepticus 141uncontrolled nature of these six cases. It may be that
the patient’s other AEDs finally took effect at the
same timeLEVwasadded,giving theappearance that
LEV was responsible. Serum levels of LEV could have
documented adequate absorption from the NG tube,
and should be obtained in future studies. (In this
observational study, clinical response was the treat-
ment endpoint, and the practical value of serum LEV
levels was limited due to their 1-week turn around
time.) However, the promptness and consistency of
the patients’ response after addition of LEV favors a
therapeutic action. (In Case #5, the patient
responded after receiving LEV and lamotrigine
together, making it difficult to discern whether it
was the LEV or lamotrigine, or combination that
resulted in seizure control).
As status epilepticus becomes more difficult to
treat the longer it continues, one can only speculate
whether LEV would have beenmore effective if used
as initial treatment, rather than as adjunctive ther-
apy late in the clinical course. These positive results
combinedwith LEV’s broad spectrum efficacy, favor-
able pharmacokinetics and side effect profile sug-
gest that LEV may be beneficial as adjunctive
treatment of status epilepticus. Randomized con-
trolled trials of LEV as a treatment for status epi-
lepticus should be considered.Acknowledgment
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